A four-kallikrein panel predicts prostate cancer in men with recent screening: Data from the european randomized study of screening for prostate cancer, Rotterdam

Clinical Cancer Research

Volumn 16, Issue 12, 2010, Pages 3232-3239

  Vickers, Andrew J ^a   Cronin, Angel M ^a   Roobol, Monique J ^b   Savage, Caroline J ^a   Peltola, Mari ^c   Pettersson, Kim ^c   Scardino, Peter T ^a   Schröder, Fritz H ^b   Lilja, Hans ^a,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TURKU   (Finland)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN 2; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; BIOPSY; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; MALE; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953715079     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0122     Document Type: Article

References (25)

1. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
2. Andriole GL, Crawford ED, Grubb RL III, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
3. Ulmert D, Serio AM, O'Brien MF, et al. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol 2008;26:835-41. (Pubitemid 351398073)
4. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009;101:1325-9.
5. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med 2008;6:19.
6. Vickers A, Cronin A, Roobol M, et al. Reducing unnecessary biopsy during prostate cancer screening using a four kallikrein panel: an independent replication. J Clin Oncol 2010 Apr 26. [Epub ahead of print].
7. Vickers AJ, Cronin AM, Aus G, et al. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer 2010 Mar 24. [Epub ahead of print].
8. Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol 2009 Aug 7. [Epub ahead of print].
9. Roobol MJ, Kirkels WJ, Schroder FH. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 2003;92 Suppl 2:48-54.
10. Vaisanen V, Peltola MT, Lilja H, Nurmi M, Pettersson K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments. Anal Chem 2006;78:7809-15. (Pubitemid 44037747)
11. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
12. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006;26:565-74.
13. Schroder FH, van den Bergh RC, Wolters T, et al. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur Urol 2010;57:256-66.
14. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297-301.
15. Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, Catalona WJ. Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program. Urology 2008;71:1016-9.
16. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70. (Pubitemid 41002840)
17. Vickers AJ, Ulmert D, Serio AM, et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer 2007;121:2212-7. (Pubitemid 47585600)
18. Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99, discussion 98-9.
19. Mikolajczyk SD, Catalona WJ, Evans CL, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004;50:1017-25.
20. Nam RK, Zhang WW, Trachtenberg J, et al. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol 2003;21:2312-9. (Pubitemid 46621869)
21. Martin BJ, Cheli CD, Sterling K, et al. Prostate specific antigen isoforms and human glandular kallikrein 2-which offers the best screening performance in a predominantly black population? J Urol 2006;175:104-7.
22. Martin BJ, Finlay JA, Sterling K, et al. Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA). Prostate Cancer Prostatic Dis 2004;7:132-7.
23. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.
24. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-84. (Pubitemid 43121812)
25. Ulmert D, Becker C, Nilsson JA, et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem 2006;52:235-9. (Pubitemid 43185484)